Ultragenyx Pharmaceutical Inc. (RARE)

♥ 448 Thanks from members

Ultragenyx (RARE) demonstrates robust commercial growth and a narrower net loss in Q2 2026, highlighted by the milestone accelerated approval of its first gene therapy, GENGLYCOS (DTX401), for GSDIa alongside a valuable Priority Review Voucher.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Emil Kakkis Leadership: Emil Kakkis (CEO) Leadership: Theodore Hu (CFO) Holder: FMR LLC Holder: BlackRock, Inc. Holder: Vanguard Group Crysvita Mepsevii Dojolvi #Ultragenyx #RARE stock #rare disease biopharma #genetic disorders #Crysvita